Role of the nitric oxide/cyclic GMP/Ca2+ signaling pathway in the pyrogenic effect of interleukin-1β

被引:23
作者
Palmi, M [1 ]
Meini, A [1 ]
机构
[1] Univ Siena, Ist Sci Farmacol, I-53100 Siena, Italy
关键词
interleukin-1; beta; fever; intracellular Ca2+; nitric oxide; cyclic GMP; intracellular Ca2+ stores; human astrocytoma cells; rat striatum; neurotoxicity;
D O I
10.1385/MN:25:2:133
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Interleukin-1beta (IL-1beta) has a wide spectrum of inflammatory, metabolic, haemopoietic, and immunological properties. Because it produces fever when injected into animals and humans, it is considered an endogenous pyrogen. There is evidence to suggest that Ca2+ plays a critical role in the central mechanisms of thermoregulation, and in the intracellular signaling pathways controlling fever induced by IL-1beta and other pyrogens. Data from different labs indicate that Ca2+ and Na+ determine the temperature set point in the posterior hypothalamus (PH) of various mammals and that changes in Ca2+ and PGE(2) concentrations in the cerebrospinal fluid (CSF) of these animals are associated with IL-1beta-induced fever. Antipyretic drugs such as acetylsalicylic acid, dexamethasone, and lipocortin 5-(204-212) peptide counteract IL-1beta-induced fever and abolish changes in Ca2+ and PGE2 concentrations in CSF. In vitro studies have established that activation of the nitric oxide (NO)/cyclic GMP (cGMP) pathway is part of the signaling cascade transducing Ca2+ mobilization in response to IL-1beta and that the ryanodine (RY)- and inositol-(1,4,5)-trisphosphate (IP3)- sensitive pools are the main source of the mobilized Ca2+. It is concluded that the NO/cGMP/Ca2+ pathway is part of the signaling cascade subserving some of the multiple functions of IL-1beta.
引用
收藏
页码:133 / 147
页数:15
相关论文
共 113 条
[11]  
Brune B, 1996, REV PHYSIOL BIOCH P, V127, P1, DOI 10.1007/BFb0048263
[12]  
BURCH RM, 1988, P NATL ACAD SCI USA, V85, P3606
[13]   PURIFICATION, CLONING, EXPRESSION AND BIOLOGICAL CHARACTERIZATION OF AN INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN [J].
CARTER, DB ;
DEIBEL, MR ;
DUNN, CJ ;
TOMICH, CSC ;
LABORDE, AL ;
SLIGHTOM, JL ;
BERGER, AE ;
BIENKOWSKI, MJ ;
SUN, FF ;
MCEWAN, RN ;
HARRIS, PKW ;
YEM, AW ;
WASZAK, GA ;
CHOSAY, JG ;
SIEU, LC ;
HARDEE, MM ;
ZURCHERNEELY, HA ;
REARDON, IM ;
HEINRIKSON, RL ;
TRUESDELL, SE ;
SHELLY, JA ;
EESSALU, TE ;
TAYLOR, BM ;
TRACEY, DE .
NATURE, 1990, 344 (6267) :633-638
[14]   Role of nitric oxide and its intracellular signalling pathways in the control of Ca2+ homeostasis [J].
Clementi, E .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (06) :713-718
[15]  
CLEMENTI E, 1995, MOL PHARMACOL, V47, P517
[16]   INTERLEUKIN-1 RECEPTOR ANTAGONIST - EFFECTIVENESS AGAINST INTERLEUKIN-1 FEVER [J].
COCEANI, F ;
LEES, J ;
REDFORD, J ;
BISHAI, I .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (12) :1590-1596
[17]   CENTRAL ADMINISTRATION OF INTERLEUKIN 1 ELICITS HYPERINSULINEMIA IN RATS [J].
CORNELL, RP ;
SCHWARTZ, DB .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (03) :R772-R777
[18]   THE PHARMACOLOGY OF FEVER [J].
DASCOMBE, MJ .
PROGRESS IN NEUROBIOLOGY, 1985, 25 (04) :327-373
[19]   A STUDY OF THE PYROGENIC ACTIONS OF INTERLEUKIN-1-ALPHA AND INTERLEUKIN-1-BETA - INTERACTIONS WITH A STEROIDAL AND A NONSTEROIDAL ANTIINFLAMMATORY AGENT [J].
DAVIDSON, J ;
MILTON, AS ;
ROTONDO, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 100 (03) :542-546
[20]   ANTIPYRETIC ACTIONS OF HUMAN RECOMBINANT LIPOCORTIN-1 [J].
DAVIDSON, J ;
FLOWER, RJ ;
MILTON, AS ;
PEERS, SH ;
ROTONDO, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 102 (01) :7-9